Skip to main content

Matulane (procarbazine) Disease Interactions

There are 5 disease interactions with Matulane (procarbazine):

Major

Antineoplastics (applies to Matulane) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  4. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  5. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  6. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  7. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  8. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  9. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  10. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  11. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  12. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
  13. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  14. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  15. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  16. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  17. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  18. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL.
  19. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  20. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  21. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  22. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
  23. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  24. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  25. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  26. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  27. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  28. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  29. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  30. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  31. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
View all 31 references
Major

Procarbazine (applies to Matulane) bleeding disorders

Major Potential Hazard, Moderate plausibility.

Procarbazine induces myelosuppression, including thrombocytopenia. Bleeding tendencies have included petechiae, purpura, epistaxis, hemoptysis, hematuria, and melena. Therapy with procarbazine should be administered cautiously in patients with bleeding tendencies. Patients should be instructed to immediately report any signs or symptoms of bleeding. Procarbazine should be withheld and/or discontinued if bleeding occurs. Therapy should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3. Clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
Major

Procarbazine (applies to Matulane) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever

Procarbazine induces myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during procarbazine therapy. Therapy with procarbazine is contraindicated in patients with inadequate bone marrow reserve as demonstrated by bone marrow aspiration, and should be administered after cautious consideration in patients whose bone marrow reserve may be severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be withheld if leukocyte counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3. Close monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
Moderate

Procarbazine (applies to Matulane) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Procarbazine is metabolized by liver and kidney. Patients with hepatic impairment may be at increased risk for toxicity from procarbazine therapy at recommended dosages. Therapy with procarbazine should be administered cautiously in patients with compromised hepatic function.

References

  1. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
Moderate

Procarbazine (applies to Matulane) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Procarbazine is metabolized by the liver and kidney. Approximately 70 % of procarbazine is excreted in the urine. Patients with renal impairment may be at increased risk for toxicity from procarbazine therapy at recommended dosages. Therapy with procarbazine should be administered cautiously in patients with compromised renal function.

References

  1. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.

Matulane (procarbazine) drug interactions

There are 483 drug interactions with Matulane (procarbazine)

Matulane (procarbazine) alcohol/food interactions

There is 1 alcohol/food interaction with Matulane (procarbazine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.